联环药业因垄断协议被罚没6100余万元

Core Viewpoint - Lianhuan Pharmaceutical (600513.SH) has been fined approximately 61.04 million yuan for violating antitrust laws by engaging in price-fixing agreements related to the raw material dexamethasone phosphate sodium, which restricted competition in the market [1][2]. Group 1: Regulatory Actions - The Tianjin Municipal Market Supervision Administration issued an administrative penalty decision against Lianhuan Pharmaceutical for colluding with competitors to fix prices, violating antitrust regulations [1]. - The company has submitted a hearing application to contest the decision, but the hearing did not overturn the factual findings of the enforcement personnel [4]. Group 2: Financial Impact - The penalty amount represents 2.83% of the company's audited revenue and 72.53% of its net profit attributable to shareholders for the most recent fiscal year [2]. - In 2024, Lianhuan Pharmaceutical reported total revenue of 2.16 billion yuan, a decrease of 0.63% year-on-year, and a net profit of 84.16 million yuan, down 37.66% from the previous year [5][6]. Group 3: Market Context - Dexamethasone is a corticosteroid used for its anti-inflammatory and immunosuppressive properties, and it has been included in the treatment protocols for severe COVID-19 cases in China [4]. - Lianhuan Pharmaceutical, along with Tianjin Pharmaceutical and Xianju Pharmaceutical, are the only domestic companies with approval for dexamethasone phosphate sodium injection [4].